At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 133 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
In Brief
A Phase 2 clinical trial evaluating Dasatinib for Leukemia. Completed, enrolled 133 participants across 174 sites in 18 countries.
Detailed Summary
The purpose of this study is to determine whether dasatinib is safe and effective in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia (ALL), accelerated or blast phases CML who relapse after imatinib or who are resistant or intolerant to imatinib. The side effects of this oral investigational drug in children and adolescents will be evaluated
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesArgentina, Australia, Brazil, Canada, France, Germany, India, Italy, Mexico, Netherlands, Romania, Russia, Singapore, South Africa, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartMar 2009
Primary CompletionSep 2016
Study CompletionJan 2025
TodayJul 2026
First PostedOct 22, 2008
Enrollment StartMar 20, 2009
Primary CompletionSep 1, 2016
Study CompletionJan 27, 2025
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 17.7 years ago
Interventions
Dasatinibdrug